GlassScriptPhysician profile
Kenneth W Lee
NPI 1417023227
$8,108.54
in general payments reported to CMS, 2019-2025
28 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $663 · 2021: $650 · 2022: $1,039 · 2023: $1,791 · 2024: $1,291 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,943.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,755.45 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,084.11 | 2019-2025 | |
| Janssen Biotech, INC. | $1,061.07 | 2022-2025 | Stelara, Tremfya, Simponi |
| Phathom Pharmaceuticals, INC. | $611.24 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $489.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $404.36 | 2019-2024 | Linzess |
| Ardelyx, INC. | $390.92 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $342.98 | 2019-2024 | Entyvio, Eohilia |
| Intercept Pharmaceuticals, INC. | $225.46 | 2019-2025 | Ocaliva |
| Lilly USA, LLC | $213.10 | 2024-2025 | Omvoh |
| Pfizer INC. | $199.77 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $172.43 | 2021-2024 | Dificid |
| Redhill Biopharma INC. | $171.34 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Qol Medical, LLC | $169.25 | 2022-2023 | Sucraid |
| Genzyme Corporation | $160.56 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $144.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $108.35 | 2022-2023 | Dupixent |
| Celltrion USA INC. | $103.16 | 2025 | Vegzelma |
| Novo Nordisk INC | $58.91 | 2025 | Wegovy |
| Celgene Corporation | $55.80 | 2021-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $32.99 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $29.41 | 2021-2023 | |
| Vivus LLC | $24.89 | 2024 | Pancreaze |
| Aimmune Therapeutics, INC. | $23.63 | 2024 | |
| Olympus America INC. | $22.17 | 2025 | Endoclot Phs |
| Braintree Laboratories, INC. | $18.75 | 2023 | Sutab |
| Albireo Pharma, INC. | $18.30 | 2024 | Iqirvo |
| Ferring Pharmaceuticals INC. | $15.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.